Research & Development

R&D Overview Our R&D Approach Pipeline Technology Platforms Manufacturing

Other Information

Clinical Trials Expanded Access Investigator Sponsored Studies

Pipeline

Pipeline of Key Proprietary Products

Our pipeline of key proprietary products includes a late-stage drug candidate for the treatment of schizophrenia and the treatment of bipolar I disorder, and an early-stage drug candidate in immuno-oncology.

Development Candidates

ALKS 3831
Schizophrenia, Bipolar I Disorder

NDA Submitted

ALKS 4230
Immuno-oncology

ARTISTRY-1: Intravenous Administration of ALKS 4230 as Monotherapy and in Combination With Pembrolizumab

Phase 1/2: Ongoing

ARTISTRY-2: Subcutaneous Administration of ALKS 4230 as Monotherapy and in Combination With Pembrolizumab

Phase 1/2: Ongoing

ION-01: Intravenous Administration of ALKS 4230 in Combination With Pembrolizumab
In collaboration with the Fred Hutchinson Cancer Research Center

Phase 2: Planned